高压氧治疗视网膜动脉闭塞的疗效和安全性:系统回顾和荟萃分析。

IF 2.2 4区 医学 Q2 CLINICAL NEUROLOGY
Mohamed Elfil, Hanin Sabet, Abdallah Abbas, Ahmed Bayoumi, Hazem S Ghaith, Mohamed Hesham Ghoneem, Amr Shaarawy, Monsef Ibrahim Kharboush, Mohammad Aladawi, Zaid Najdawi, Chaitanya Medicherla, Daniel A Schwartz, Kelly A Hutcheson, Daniel Elefant, Gurmeen Kaur, Chirag D Gandhi, Fawaz Al-Mufti
{"title":"高压氧治疗视网膜动脉闭塞的疗效和安全性:系统回顾和荟萃分析。","authors":"Mohamed Elfil, Hanin Sabet, Abdallah Abbas, Ahmed Bayoumi, Hazem S Ghaith, Mohamed Hesham Ghoneem, Amr Shaarawy, Monsef Ibrahim Kharboush, Mohammad Aladawi, Zaid Najdawi, Chaitanya Medicherla, Daniel A Schwartz, Kelly A Hutcheson, Daniel Elefant, Gurmeen Kaur, Chirag D Gandhi, Fawaz Al-Mufti","doi":"10.1017/cjn.2025.10364","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.</p><p><strong>Methods: </strong>We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).</p><p><strong>Results: </strong>Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: -0.63, 95% CI: [-1.14, -0.12], <i>p</i> = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.</p><p><strong>Conclusions: </strong>HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-10"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Hyperbaric Oxygen Therapy for Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.\",\"authors\":\"Mohamed Elfil, Hanin Sabet, Abdallah Abbas, Ahmed Bayoumi, Hazem S Ghaith, Mohamed Hesham Ghoneem, Amr Shaarawy, Monsef Ibrahim Kharboush, Mohammad Aladawi, Zaid Najdawi, Chaitanya Medicherla, Daniel A Schwartz, Kelly A Hutcheson, Daniel Elefant, Gurmeen Kaur, Chirag D Gandhi, Fawaz Al-Mufti\",\"doi\":\"10.1017/cjn.2025.10364\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.</p><p><strong>Methods: </strong>We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).</p><p><strong>Results: </strong>Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: -0.63, 95% CI: [-1.14, -0.12], <i>p</i> = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.</p><p><strong>Conclusions: </strong>HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.</p>\",\"PeriodicalId\":56134,\"journal\":{\"name\":\"Canadian Journal of Neurological Sciences\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/cjn.2025.10364\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/cjn.2025.10364","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:视网膜动脉闭塞(RAO)是一种视力威胁疾病,治疗选择有限。高压氧治疗(HBOT)已成为一种潜在的治疗方法,可以增强视网膜氧合和挽救缺血组织,尽管其有效性和安全性仍存在争议。方法:我们遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南和Cochrane干预措施系统评价手册。数据库检索到2024年11月,以比较HBOT与对照组在RAO患者中的研究。偏倚风险采用纽卡斯尔-渥太华量表进行评估。meta分析评估了视力(VA)、最佳矫正视力(BCVA)和不良事件(ae)。结果:9项研究共499例患者(286例HBOT, 213例非HBOT)符合纳入标准。敏感性分析显示,HBOT与BCVA改善相关(MD: -0.63, 95% CI: [-1.14, -0.12], p = 0.01)。在未纠正的VA或改善线中未观察到显著差异。HBOT组的ae包括癫痫发作(1.47%)、耳气压伤(1.65%)和鼻出血(0.83%)。值得注意的是,与对照组相比,HBOT与较低的新生血管性青光眼(7.89%对15.79%)和中风(4.3%对16.6%)发生率相关。结论:HBOT具有改善RAO患者视力的潜力,特别是BCVA患者,具有良好的安全性。然而,研究之间的异质性和有限的样本量突出了需要强有力的前瞻性试验来阐明其在RAO管理中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy and Safety of Hyperbaric Oxygen Therapy for Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.

Background: Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.

Methods: We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).

Results: Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: -0.63, 95% CI: [-1.14, -0.12], p = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.

Conclusions: HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
3.30%
发文量
330
审稿时长
4-8 weeks
期刊介绍: Canadian Neurological Sciences Federation The Canadian Journal of Neurological Sciences is the official publication of the four member societies of the Canadian Neurological Sciences Federation -- Canadian Neurological Society (CNS), Canadian Association of Child Neurology (CACN), Canadian Neurosurgical Society (CNSS), Canadian Society of Clinical Neurophysiologists (CSCN). The Journal is a widely circulated internationally recognized medical journal that publishes peer-reviewed articles. The Journal is published in January, March, May, July, September, and November in an online only format. The first Canadian Journal of Neurological Sciences (the Journal) was published in 1974 in Winnipeg. In 1981, the Journal became the official publication of the member societies of the CNSF.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信